Detecting and targeting specific antibody idiotypes is key for developing effective tracking assays for drug antibodies. Developing monoclonal and eventually recombinant anti-drug idiotype antibodies for such purposes has been possible but time-consuming and expensive.
Ankyrons provide a clear and powerful solution to this problem. Selected directly in vitro from our Teralibrary we already offer a growing range anti-drug idiotype Ankyrons, including against already approved therapeutic antibodies for Herceptin® (trastuzumab), Erbitux® (cetuximab), Avastin® (bevacizumab), Humira® (adalimumab), and Rituxan® (rituximab). Using guided selection we are able to select idiotype-specific Ankyrons quickly confirming non-binding to unrelated drug antibodies and other Ig subtypes.
Contact us with your Custom Ankyron™ requirements or Request a Quote for us to make a quantum leap in your idiotype targeting project.
Data for Avastin® (bevacizumab) idiotype-specific Ankyron binding
Figure. Avastin® (bevacizumab) idiotype-specific Ankyron binding. Non-binding to other drug antibodies and Ig isotypes/sub-classes is shown at high signal-to-noise ratio.
